Search

Renal cell carcinomas, which comprise the majority of primary kidney tumors, present diverse challenges in treatment planning. This case report explores the application of simultaneous partial nephrectomy and radiofrequency (RF) ablation in a patient with a solitary kidney, emphasizing the significance of specific interventions. A 52-year-old female patient who underwent radical nephrectomy presented with right flank pain and hematuria. Contrast-enhanced computed tomography revealed exophytic and calyceal system-extending lesions in the right kidney. A multidisciplinary approach involving interventional radiology and nephrology facilitated preoperative preparation. The patient underwent simultaneous partial nephrectomy and RF ablation in a single session, resulting in favorable outcomes. This meta-analysis highlighted radical nephrectomy's association with chronic kidney disease, emphasizing the need for specialized treatment approaches. Ablative treatment was associated with superior perioperative outcomes, whereas partial nephrectomy exhibited higher urological complication rates. Minimally invasive techniques are crucial, especially for solitary kidney cases and small renal tumors. Simultaneous partial nephrectomy and RF ablation are effective for managing exophytic and calyceal system-extending masses in solitary kidneys. The preservation of renal function is of paramount importance, prompting consideration of ablative treatment alongside partial nephrectomy. Despite limited evidence, ablative therapies offer a viable alternative for frail and comorbid patients, ensuring long-term oncological durability and superior preservation of renal function. Keywords:Ablation, partial nephrectomy, radical nephrectomy, radiofrequency ablation, renal cell carcinoma, renal tumor, tumor: [ABSTRACT FROM AUTHOR]

Purpose: To investigate the proportion of neoadjuvant chemotherapy (NAC) use in patients with muscle invasive bladder cancer before radical cystectomy and the approach of urologists to this subject. Materials and Methods: We invited 242 urologists during the 12th International Urooncology Congress in Turkey to answer a self-administered questionnaire. The questionnaire included questions related to radical cystectomy, lymph node dissection and neoadjuvant chemotherapy that had been performed in patients with muscle invasive bladder cancer by the urologist. Results: The median number of radical cystectomy operations was 20 per year. 122 (50.5%) of 242 urologists had used neoadjuvant chemotherapy for the treatment of muscle invasive bladder cancer before radical cystectomy. The mean rate of neoadjuvant chemotherapy use by these urologists (n=122) was 28.46%. The most common reasons for not using neoadjuvant chemotherapy by urologists in Turkey were as follows: (i) neoadjuvant chemotherapy might lead to a decrease in the cure rate of radical cystectomy due to delayed surgery (ii) complication rate of radical cystectomy might be elevated and the surgery might be complicated by NAC use. Conclusion: Although the European Association of Urology (EAU) guidelines panel on muscle invasive bladder cancer recommends using NAC in T2-T4a bladder, the rate of neoadjuvant chemotherapy use was still found to be low in our country because urologists have concerns about adverse effects NAC on radical cystectomy. [ABSTRACT FROM AUTHOR]

Objective: To compare bladder wall thickness (BWT) between female patients with overactive bladder (OAB) and aged-matched healthy controls. Material and methods: Thirty-six female patients with OAB and 31 healthy women were enrolled in the present prospective observational study. Qmax and Qave were measured by using uroflowmetry in all of the women in the patient and control groups, and also maximum bladder capacity (MBC), post- void residual urine (PVRU), prevoiding and postvoiding BWT were measured by using transabdominal ultrasound. Lower urinary tract symptoms of the participants were assessed by using Overactive Bladder Version-8 (OAB-V8) and International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF). All of the data were statistically compared between the patient and control groups. In the patient group, the relationships between parameters were evaluated correlation analysis. Results: The mean age of the patients and controls were similar (respectively, 45.58±12.35 and 44.21±11.60 years (p=0.68). The mean pre- and post-voiding BWT, OAB-V8 and ICIQ-SF scores of the patients were significantly higher than the controls. In the patient group, the moderate positive correlations between BWT with Qmax (p=0.02) and Qave (p=0.02) were found. Conclusion: This study showed that the BWTs of the female patients with OAB are higher than those of healthy women. Further studies should investigate the changes in BWT of patients with OAB after treatment of OAB. [ABSTRACT FROM AUTHOR]

Purpose: Patients receiving treatment for benign prostate hyperplasia may have persistent storage symptoms. There has been increasing debate on the precision and accuracy of the International Prostate Symptom Score questionnaires over other questionnaires in evaluating all the complaints of lower urinary tract symptoms (LUTS). The aim of this study was to perform the validity and reliability analysis of the Turkish version of the Internatinal Consultation on Incontinence Questionnaire-Male LUTS (ICIQ-MLUTS). Methods: Linguistic validation was studied (i.e., translation and back translation). Intelligibility was completed between October 2013 and November 2013. Data was collected between November 2013 and March 2014. The stability and reliability of the form were measured with the Cronbach test. Results: In total, 117 male patients were included in the study. At the first visit, the mean age of the patients was 59 years (range, 18-84 years). For reliability, the Cronbach alpha value was 0.798, demonstrating the internal consistency of the form (r>0.7). The internal consistency of each question was examined separately and found to be over 0.7. For the evaluation of test-retest reliability, the test was administered to 116 patients for a second time with an interval of 2-4 weeks. The first and second test scores for each question were found to be correlated (r=0.741). Conclusions: ICIQ-MLUTS is a new questionnaire, which can be used for evaluating male LUTS in Turkey. We believe that the Turkish version of the ICIQ-MLUTS is an important breakthrough in our country. [ABSTRACT FROM AUTHOR]

Objectives: The aim of our study was to compare the effects on quality of life (QoL) and stone-free rate (SFR) of percutaneous nephrolithotomy (PNL) and retrograde intrarenal surgery (RIRS) in patients with renal stones 2-4cm., Materials and Methods: A total of 102 patients with renal pelvis stones were enrolled in this prospective controlled study, of which 52 were performed RIRS and 50 with PNL. The QoL was evaluated by using Short From-36 pre- and post-operatively. Also, the surgical data of all patients during and after the operations were compared between the 2 groups., Results: The mean age, body mass index, stone size and density of the patients in the 2 groups were statistically similar ( p > 0.05). The SFR of PNL and RIRS were found 94% (47/50) and 73% (38/52), respectively ( p < 0.01). There were no statistically differences between operation times, minor complication rates and Short From-36 scores of the 2 groups. Hospitalization times were 1.13 ± 0.34days for RIRS and 2.9 ± 5.7days for PNL ( p < 0.05). While the blood transfusion rate of PNL group was 8% (4/50), none patient was made blood transfusion in RIRS., Conclusions: The results of our study show that the blood transfusion rates and hospitalization times of RIRS group are significantly lower than PNL for management of renal pelvis stone 2-4cm. Despite these advantages of RIRS, the SFR is significantly lower than PNL for these stones. The effects on QoL of the both interventions before and after surgery were similar., Competing Interests: There are no conflicts of interest to be stated for the corresponding author and all co-authors., (Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc.)